

Figure 2: Participant Assessments

Time Point	S	B	1° Follow Up & Treatment Period															2° Follow Up
Day	<B	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15-28	29-90
Eligibility	X																	
Consent	X																	
Demographics ¹		X																
Medical History		X																
Randomisation		X																
Concomitant Medication		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Intervention Supply		X																
Health Status Assessment ²		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Medication Adherence		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Blood Pressure		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
Blood Pathology ³		X	X		X		X		X		X					X		
Hospitalisation & Mortality																		X

S = Screening, B = Baseline, 1° = Primary, 2° = Secondary

¹ Demographics includes: Date of Birth, Sex, Ethnicity, Weight, Height, Smoking Status, COVID-19 diagnosis, comorbidities

² Health Status Assessment includes: Hospital Admission status, Ventilation status, Supplemental Oxygen Status, Intensive Care Unit Admission status, Mortality status, Dialysis Status & Acute Kidney Injury status

³ Blood Pathology includes: Potassium, Serum Creatinine, creatinine kinase, estimated glomerular filtration rate, white cell count, lymphocytes, D-dimer, C-reactive protein